The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy

A Basu - Pharmacology & therapeutics, 2022 - Elsevier
Cell death by apoptosis and permanent cell cycle arrest by senescence serve as barriers to
the development of cancer. Chemotherapeutic agents not only induce apoptosis, they can …

Mitochondrial glutathione: recent insights and role in disease

M Marí, E de Gregorio, C de Dios, V Roca-Agujetas… - Antioxidants, 2020 - mdpi.com
Mitochondria are the main source of reactive oxygen species (ROS), most of them deriving
from the mitochondrial respiratory chain. Among the numerous enzymatic and non …

BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models

U Rauh, G Wei, M Serrano-Wu, G Kosmidis… - Nature Cancer, 2024 - nature.com
The MCL1 gene is frequently amplified in cancer and codes for the antiapoptotic protein
myeloid cell leukemia 1 (MCL1), which confers resistance to the current standard of care …

Targeted therapy for hepatocellular carcinoma: old and new opportunities

C Laface, P Fedele, FM Maselli, F Ambrogio, C Foti… - Cancers, 2022 - mdpi.com
Simple Summary Hepatocellular carcinoma (HCC) is the most frequent primitive cancer of
the liver, accounting for 90% of all recorded cases. HCC is the third most common cause of …

[HTML][HTML] It's time to die: BH3 mimetics in solid tumors

S Kehr, M Vogler - Biochimica et Biophysica Acta (BBA)-Molecular Cell …, 2021 - Elsevier
The removal of cells by apoptosis is an essential process regulating tissue homeostasis.
Cancer cells acquire the ability to circumvent apoptosis and survive in an unphysiological …

A feedback loop of PPP and PI3K/AKT signal pathway drives regorafenib-resistance in HCC

H Yang, D Chen, Y Wu, H Zhou, W Diao, G Liu… - Cancer & Metabolism, 2023 - Springer
Background Hepatocellular carcinoma (HCC) is a principal type of liver cancer with high
incidence and mortality rates. Regorafenib is a novel oral multikinase inhibitor for second …

Hepatocellular carcinoma: molecular pathogenesis and therapeutic advances

B Cucarull, A Tutusaus, P Rider, T Hernáez-Alsina… - Cancers, 2022 - mdpi.com
Simple Summary Patients with unresectable hepatocellular carcinoma (HCC), the most
common primary tumor of the liver, have poor prognosis and are increasing worldwide. The …

Recent trends and advances in novel formulations as an armament in Bcl-2/Bax targeted breast cancer

S Samia, PS Chary, O Khan, NK Mehra - International Journal of …, 2024 - Elsevier
Breast cancer (BC) remains a significant health burden worldwide, necessitating the
development of innovative therapeutic strategies. The B-cell lymphoma 2 (Bcl-2) family …

Antioxidants threaten multikinase inhibitor efficacy against liver cancer by blocking mitochondrial reactive oxygen species

B Cucarull, A Tutusaus, T Hernáez-Alsina… - Antioxidants, 2021 - mdpi.com
Sorafenib and regorafenib, multikinase inhibitors (MKIs) used as standard chemotherapeutic
agents for hepatocellular carcinoma (HCC), generate reactive oxygen species (ROS) during …

Mitochondrial quality control in hepatocellular carcinoma

J Bian, D Zhang, Y Wang, H Qin, W Yang, R Cui… - Frontiers in …, 2021 - frontiersin.org
Mitochondria participate in the progression of hepatocellular carcinoma (HCC) by modifying
processes including but not limited to redox homeostasis, metabolism, and the cell death …